Effect of daily azithromycin therapy and adherence on readmission risk in COPD.

Patients with Chronic Obstructive Pulmonary Disease (COPD) frequently experience unplanned hospital readmissions leading to increased morbidity [1]. The European Union COPD audit found that 35% of patients admitted with acute exacerbation of COPD (AECOPD) were readmitted within 90 days [2]. In the United States, 22% of patients admitted with AECOPD experienced a 30-day readmission, motivating financial policies to incentivize readmission reduction [1]. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of interest: Dr. Krishnan reports grants from NHLBI/NIH, during the conduct of the study. Conflict of interest: Ms. Voelker has nothing to disclose. Conflict of interest: Dr. Connett has nothing to disclose. Conflict of interest: Dr. Niewoehner reports grants from National Institute of Health, during the conduct of the study; personal fees from Boehringer Ingelheim, personal fees from Astrazeneca, personal fees from GlaxoSmithKline, outside the submitted work. Conflict of interest: Dr. Albert has nothing to disclose. Conflict of interest: Dr. Scanlon reports grants from National Heart Lung and Blood Institute, during the conduct of the study; grants from Astra Zeneca, grants from Boehringer Ingelheim, grants from Forest Pharmaceuticals, grants from GlaxoSmithKline, grants from Novartis, grants from Pearl Therapeutics, other from Boehringer Ingelheim, other from GlaxoSmithKline, outside the submitted work. Conflict of interest: Dr. Dransfield reports grants from NHLBI, during the conduct of the study; grants from Department of Defense , personal fees and other from Boehringer Ingeheim, personal fees and other from GlaxoSmithKline, other from Novartis, personal fees and other from AstraZeneca, other from Yungjin, other from PneumRx/BTG, other from Pulmonx, personal fees from Genentech, personal fees and other from Boston Scientific , outside the submitted work. Conflict of interest: Dr. Han reports personal fees from BI, personal fees from GSK, personal fees from AZ, non-financial support from Novartis, non-financial support from Sunovion, outside the submitted work. Conflict of interest: Dr. Martinez reports non-financial support from GlaxoSmithKline, during the conduct of the study; personal fees from Continuing Education, personal fees from Forest Laboratories, other from Janssen, personal fees from GlaxoSmithKline, personal fees from Nycomed/Takeda, personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Bellerophon (formerly Ikaria), personal fees from Genentech, personal fees from Novartis, personal fees from Pearl, personal fees from Roche, personal fees from Sunovion, personal fees from Theravance, personal fees from CME Incite, personal fees from Annenberg Center for Health Sciences at Eisenhower, personal fees from Integritas, personal fees from InThought, personal fees from National Association for Continuing Education, personal fees from Paradigm Medical Communications, LLC, personal fees from PeerVoice, personal fees from UpToDate, personal fees from Haymarket Communications, personal fees from Western Society of Allergy and Immunology, from Proterixbio (formerly Bioscale), personal fees from Unity Biotechnology, personal fees from ConCert Pharmaceuticals, personal fees from Lucid, personal fees from Methodist Hospital, personal fees from Columbia University, personal fees from Prime Healthcare Ltd, personal fees from WebMD, personal fees from PeerView Network, personal fees from California Society of Allergy and Immunology, personal fees from Chiesi, personal fees from Puerto Rico Thoracic Society, outside the submitted work. Conflict of interest: Dr. Criner reports grants from Boehringer- Ingelheim, grants from Novartis, grants from Astra Zeneca, grants from Respironics, grants from MedImmune, grants from Actelion, grants from Forest, grants from Pearl , grants from Ikaria , grants from Aeris , grants from PneumRx, grants from Pulmonx , other from HGE Health Care Solutions, Inc, other from Amirall, other from Boehringer- Ingelheim, other from Holaira, outside the submitted work.